NASDAQ:CNTX • US21077P1084
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CONTEXT THERAPEUTICS INC (CNTX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-22 | Jones Trading | Initiate | Buy |
| 2025-11-06 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-16 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-02 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-09-18 | Guggenheim | Initiate | Buy |
| 2025-08-07 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-26 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-05-08 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-29 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-21 | William Blair | Initiate | Outperform |
| 2025-04-09 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-21 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-15 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-08 | JMP Securities | Initiate | Market Outperform |
| 2024-11-25 | D. Boral Capital | Initiate | Buy |
| 2024-09-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-16 | Piper Sandler | Initiate | Overweight |
| 2024-05-09 | Maxim Group | Maintains | Buy -> Buy |
| 2024-05-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 388.93% | N/A 184.51% | N/A 124.40% | N/A 69.68% | N/A 53.50% | |||||||||
| EBITDA YoY % growth | -33.19M | -24.04M 27.57% | N/A | N/A | N/A | -15.37M -43.23% | -25.061M -63.05% | -29.913M -19.36% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -33.23M | -24.06M 27.60% | -5.38M | -2.57M 52.23% | -10.53M -309.73% | -15.38M -46.06% | -25.073M -63.02% | -29.924M -19.35% | N/A -23.62% | N/A -16.06% | N/A -22.85% | N/A -16.31% | N/A 23.39% | N/A 100.45% | N/A 51,016.43% | N/A 132.28% | N/A 72.38% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | -0.93 90.13% | -1.50 -61.29% | -0.53 64.67% | N/A 32.81% | N/A -17.60% | N/A 2.57% | N/A 10.00% | N/A 58.89% | N/A 308.11% | N/A 296.92% | N/A 71.78% | N/A 63.57% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.11 -166.63% | -0.11 -127.97% | -0.11 -24.25% | -0.12 -16.53% | -0.12 -15.72% | -0.10 14.99% | -0.11 -0.34% | -0.13 -13.79% | -0.14 -15.70% | -0.22 -126.32% | -0.26 -127.27% | -0.25 -85.38% |
| Revenue Q2Q % growth | N/A | N/A | N/A | |||||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -10.574M -145.34% | -11.226M -103.04% | -11.759M -20.50% | -12.415M -17.01% | -13.233M -25.15% | -10.58M 5.75% | -11.04M 6.11% | -11.961M 3.66% | -12.421M 6.14% | N/A | N/A | N/A |
All data in USD
15 analysts have analysed CNTX and the average price target is 5.1 USD. This implies a price increase of 114.29% is expected in the next year compared to the current price of 2.38.
CONTEXT THERAPEUTICS INC (CNTX) will report earnings on 2026-03-25, after the market close.
The consensus EPS estimate for the next earnings of CONTEXT THERAPEUTICS INC (CNTX) is -0.11 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering CONTEXT THERAPEUTICS INC (CNTX) is 15.